Daratumumab for Patients With Light Chain Amyloidosis

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Light Chain (AL) Amyloidosis
Interventions
DRUG

Dratumumab / Hyaluronidase Injection [Darzalex Faspro]

Daratumumab will be administered at the FDA-approved dose of 16mg/kg as an intravenous infusion.

DRUG

Pomalidomide 4 MG

Patients received oral pomalidomide on days 1-21 of a 28-days cycle from cycle 1 to 6.

PROCEDURE

autologous stem cell transplantation (ASCT)

"The ASCT protocol included mobilisation with colony-stimulating factor alone and conditioning with high-dose melphalan140-200 mg/m2~."

Trial Locations (1)

210016

RECRUITING

National Clinical Research Center for Kidney Diseases, Jinling Hospital, Nanjing

All Listed Sponsors
lead

Nanjing University School of Medicine

OTHER